Health watchdog makes U-turn over arthritis drug
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A new arthritis drug is likely to be made available to NHS patients in England and Wales after a U-turn by experts, it was revealed today.
The National Institute for Health and Clinical Excellence (Nice) produced draft guidance recommending the use of tocilizumab as a "last resort" treatment for rheumatoid arthritis patients. Earlier guidance published in March had rejected the drug because it was not considered cost-effective. The change of heart came after the health watchdog obtained new data from the medicine's manufacturer, Roche.
Tocilizumab, which is marketed as RoActemra, is already offered on the NHS in Scotland. The drug costs £10,000 per patient per year and works by targeting the immune system. It can help reduce inflammation of the joints caused by rheumatoid arthritis and prevent long-term damage.
The Nice guidance recommends offering tocilizumab to patients with moderate to severe symptoms who have failed to respond to other treatments.
The decision is still subject to appeal, but Neil Betteridge, the chief executive of charity Arthritis Care, described the move as an "important breakthrough".
Around 700,000 people in the UK suffer from rheumatoid arthritis, an auto-immune disease that attacks the joints.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments